Histoplasmosis in AIDS: advances in management

Area of Science:

• Infectious Diseases
• Immunology
• Public Health

Background:

• Histoplasmosis is a frequent opportunistic infection in individuals with Human Immunodeficiency Virus (HIV) in endemic regions.
• The incidence of histoplasmosis has decreased, correlating with advancements in antiretroviral therapy (ART).
• Infections can arise from new exposures or reactivation of latent Histoplasma capsulatum.

Purpose of the Study:

• To review the epidemiology, risk factors, clinical presentation, diagnosis, and management of histoplasmosis in HIV-infected patients.
• To highlight the impact of antiretroviral therapy on histoplasmosis incidence.
• To outline current treatment and prophylaxis strategies.

Main Methods:

• Review of existing literature on histoplasmosis in HIV-infected populations.
• Analysis of factors influencing incidence, including CD4 counts and antiretroviral therapy.
• Summary of diagnostic methods and therapeutic approaches.

Main Results:

• Major risk factors include low CD4 counts (< or = 150/microL), positive serology, and exposure to chicken coops.
• Suboptimal antiretroviral therapy may also be a risk factor.
• Diagnosis relies on cultures, antigen detection, or histopathology.
• Treatment involves amphotericin B or itraconazole for induction, followed by lifelong itraconazole maintenance.
• Itraconazole is effective for primary prophylaxis in patients with CD4 counts < or = 150/microL.

Conclusions:

• Antiretroviral therapy has significantly impacted the incidence of histoplasmosis in HIV patients.
• Prompt diagnosis and appropriate treatment, including lifelong maintenance and prophylaxis, are crucial for managing histoplasmosis.
• Understanding risk factors and clinical manifestations aids in early detection and intervention.